205 related articles for article (PubMed ID: 28978830)
1. [Treatment of relapsed or refractory acute myeloid leukemia].
Kobayashi H
Rinsho Ketsueki; 2017; 58(10):1895-1904. PubMed ID: 28978830
[TBL] [Abstract][Full Text] [Related]
2. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
[TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
[TBL] [Abstract][Full Text] [Related]
4. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
5. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
Gyurkocza B; Lazarus HM; Giralt S
Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
[TBL] [Abstract][Full Text] [Related]
7. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.
Wang ZY; Gao WH; Zhao HJ; Yin CR; Wang ZW; Tian L; Wang L; Wang LN; Jiang JL; Devillier R; Wan M; Wang JM; Huang PP; Blaise D; Hu J
Acta Haematol; 2022; 145(4):419-429. PubMed ID: 35231903
[TBL] [Abstract][Full Text] [Related]
9. Treatment of children with acute myeloid leukaemia who relapsed after allogeneic haematopoietic stem cell transplantation.
Lee JW; Jang PS; Chung NG; Cho B; Kim HK
Br J Haematol; 2013 Jan; 160(1):80-6. PubMed ID: 23106148
[TBL] [Abstract][Full Text] [Related]
10. Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.
Silla L; Dulley F; Saboya R; Kerbauy F; de Moraes Arantes A; Pezzi A; Gross LG; Paton E; Hamerschlak N
Eur J Haematol; 2017 Feb; 98(2):177-183. PubMed ID: 27621140
[TBL] [Abstract][Full Text] [Related]
11. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Leukemia; 2016 Feb; 30(2):261-7. PubMed ID: 26283567
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
14. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Aldoss I; Ji L; Haider M; Pullarkat V
Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
16. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Gutierrez-Aguirre CH; Cantú-Rodríguez OG; Gonzalez-Llano O; Salazar-Riojas R; Martinez-González O; Jaime-Pérez JC; Morales-Toquero A; Tarín-Arzaga LC; Ruiz-Argüelles GJ; Gómez-Almaguer D
Hematology; 2007 Jun; 12(3):193-7. PubMed ID: 17558694
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
18. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; Bergua J; Infante J; Esteve J; Guimaraes JE; Sierra J; Sanz MÁ
Ann Hematol; 2019 Nov; 98(11):2467-2483. PubMed ID: 31667544
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis].
Song AX; Yang DL; Wei JL; Yan ZS; Wang M; Jiang EL; Huang Y; Liu QG; Ma QL; Zhai WH; Zhang RL; Feng SZ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):161-6. PubMed ID: 20137139
[TBL] [Abstract][Full Text] [Related]
20. Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
Liu N; Ning HM; Hu LD; Jiang M; Xu C; Hu JW; Wang J; Li YH; Li BT; Lou X; Yang F; Chen JL; Su YF; Li M; Wang HY; Ren J; Feng YQ; Zhang B; Wang DH; Chen H
Leuk Res; 2015 Dec; 39(12):1375-81. PubMed ID: 26530539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]